Initiator Pharma Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

Wichtige Informationen

-29.4%

Wachstumsrate der Gewinne

-13.9%

EPS-Wachstumsrate

Biotechs Wachstum der Industrie	0.7%
Wachstumsrate der Einnahmen	n/a
Eigenkapitalrendite	-74.8%
Netto-Marge	n/a
Nächste Ertragsaktualisierung	23 Aug 2024

Jüngste Aktualisierungen vergangener Leistungen

Recent updates

Aufschlüsselung der Einnahmen und Ausgaben

Wie Initiator Pharma Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.

Gewinn- und Umsatzhistorie

OM:INIT Einnahmen, Ausgaben und Erträge (DKK Millions)
Datum	Umsatz	Allgemeine und Verwaltungskosten
31 Mar 24	-18	4
31 Dec 23	-23	4
30 Sep 23	-27	3
30 Jun 23	-29	3
31 Mar 23	-33	3
31 Dec 22	-38	3
30 Sep 22	-40	3
30 Jun 22	-43	2
31 Mar 22	-34	2
31 Dec 21	-21	1
30 Sep 21	-16	1
30 Jun 21	-10	1
31 Mar 21	-8	1
31 Dec 20	-9	1
30 Sep 20	-10	1
30 Jun 20	-9	1
31 Mar 20	-9	1
31 Dec 19	-8	1
30 Sep 19	-7	1
30 Jun 19	-9	1
31 Mar 19	-8	1
31 Dec 18	-10	1
30 Sep 18	-13	1
30 Jun 18	-11	1
31 Mar 18	-10	1
31 Dec 17	-9	1
30 Sep 17	-7	1

Initiator Pharma Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen vergangener Leistungen

Initiator Pharma A/S to Report Fiscal Year 2023 Final Results between Apr 29, 2024 and May 03, 2024

Initiator Pharma A/S to Report Q1, 2024 Results on May 10, 2024

Initiator Pharma A/S to Report Fiscal Year 2022 Results on May 01, 2023

Initiator Pharma A/S to Report Q3, 2021 Results on Nov 19, 2021

Initiator Pharma A/S to Report First Half, 2021 Results on Aug 20, 2021

Recent updates

We're Not Worried About Initiator Pharma's (STO:INIT) Cash Burn

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

Health Check: How Prudently Does Initiator Pharma (STO:INIT) Use Debt?

New minor risk - Shareholder dilution

Initiator Pharma A/S to Report Fiscal Year 2023 Final Results between Apr 29, 2024 and May 03, 2024

Initiator Pharma A/S Expands Its Position to Broader Sexual Health Franchise and Intends Business Development Efforts

Initiator Pharma A/S to Report Q1, 2024 Results on May 10, 2024

Initiator Pharma A/S, Annual General Meeting, May 24, 2024

New minor risk - Share price stability

Initiator Pharma A/S Announces Indication Expansion - Clinical Drug Candidates Active in Models of Female Sexual Dysfunction

New minor risk - Financial position

Initiator Pharma A/S Announces Positive Results from Pudafensine Phase I Pharmacokinetic Trial

Initiator Pharma A/S Completes Recruitment in Phase IIb Trial with Pudafensine (IP2015)

Initiator Pharma A/S Reports Dose-Dose-Dose-dependent Significant Erectile Dysfunction of IP 2018 in the Placebo-Controlled Phase IIa Clinical Trial of Erectile Dysfunction

Is Initiator Pharma (STO:INIT) Using Debt In A Risky Way?

Forecast breakeven date pushed back to 2024

Initiator Pharma A/S to Report Fiscal Year 2022 Results on May 01, 2023

Is Initiator Pharma (STO:INIT) Using Debt In A Risky Way?

Initiator Pharma A/S, Annual General Meeting, May 26, 2023

Initiator Pharma A/S Ready to Start Phase I Pharmacokinetics Study for New IP2015 Formulations

No independent directors

Initiator Pharma A/S Provides an Update on Its Clinical Programs

Initiator Pharma A/S Reports the Final Analysis of Positive Efficacy Data from the IPTN2021 Program Phase I Study

Initiator Pharma A/S has completed a Follow-on Equity Offering in the amount of SEK 2.499998 million.

Initiator Pharma A/S Reports Positive Efficacy Data Outcome of the Iptn2021 Program Phase I Study to Assess Pain-Reducing Effects

No independent directors

Initiator Pharma A/S announced that it expects to receive SEK 19.999995 million in funding from Adrigo Asset Management AB, Linc AB

Initiator Pharma A/S Signs Option Agreement for Late-Stage Drug Candidate

Initiator Pharma A/S Appoints Christina Guldberg as Senior Director, Clinical Development and Outcomes Research, Effective on March 1, 2022

Initiator Pharma A/S Initiates Dosing in the IPTN2021 Program Phase I Study to Assess Pain Reducing Effects

Initiator Pharma A/S Announces an Update on its Clinical Programs

Initiator Pharma A/S Receives CTA Approval for Iptn2021 Program Phase I Study to Assess Pain Reducing Effects

We're Not Worried About Initiator Pharma's (STO:INIT) Cash Burn

Initiator Pharma Includes the First Patient in Phase 2B Study with Iped2015 in Erectile Dysfunction Patients

We're Not Very Worried About Initiator Pharma's (NGM:INIT) Cash Burn Rate

Initiator Pharma Receives Approval for Phase 2a Study with IP2018

Forecast to breakeven in 2023

Initiator Pharma A/S Files its Clinical Trial Application for its Planned Phase II Study in Erectile Dysfunction Patients with IPED2015

New 90-day high: kr5.58

New 90-day low: kr4.18

Initiator Pharma A/S to Report Q3, 2021 Results on Nov 19, 2021

Initiator Pharma A/S to Report First Half, 2021 Results on Aug 20, 2021

Initiator Pharma A/S Announces Management Changes

Initiator Pharma A/S announces First patient dosed in Phase 2a trial with IP2018

Initiator Pharma A/S announced that it expects to receive SEK 23 million in funding from MAC Clinical Research Ltd

Initiator Pharma Secures Funding for IPED2015 clinical Phase 2b study

New 90-day low: kr4.69

New 90-day low: kr4.99

Initiator Pharma A/S has completed a Composite Units Offering.

Aufschlüsselung der Einnahmen und Ausgaben

Gewinn- und Umsatzhistorie

Analyse von freiem Cashflow und Gewinn

Analyse des Gewinnwachstums in der Vergangenheit

Eigenkapitalrendite

Kapitalrendite

Rendite auf das eingesetzte Kapital

Entdecken Sie starke Unternehmen, die in der Vergangenheit erfolgreich waren